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Abstract 
 
Background—Aortic valve replacement (AVR) for aortic stenosis (AS) is timed primarily on the 
development of symptoms; but late surgery can result in irreversible myocardial dysfunction and 
additional risk. This study aimed to determine whether presence of focal myocardial scar pre-
operatively was associated with long-term mortality. 
Methods—In a longitudinal observational outcome study, survival analysis was performed in 
patients with severe AS listed for valve intervention at six UK cardiothoracic centers. Patients 
underwent pre-procedure echocardiography (for valve severity assessment) and cardiovascular 
magnetic resonance for ventricular volumes, function and scar quantification between January 
2003 and May 2015. Myocardial scar was categorized into three patterns (none, infarct or non-
infarct patterns) and quantified using the full-width-at-half-maximum method as percentage of 
the left ventricle. All-cause and cardiovascular mortality were tracked for a minimum of 2 years.  
Results—674 patients with severe AS (7514years, 63% male; AV area 0.380.14cm2/m2; mean 
gradient 4618mmHg, LVEF 61.016.7%) were included. Scar was present in 51% (18% 
infarct-pattern; 33% non-infarct). Management was surgical (SAVR, n=399) or transcatheter 
(TAVR, n=275). During follow-up (median 3.6 years), 145 (21.5%) died (52 post-SAVR, 93 
post-TAVR). At multivariable analysis, the factors independently associated with all-cause 
mortality were age (HR 1.50, 95%CI: 1.11-2.04, p=0.009; scaled by epochs of 10 years), STS 
score (HR 1.12, 95%CI 1.03-1.22, p=0.007) and scar presence (HR 2.39, 95%CI 1.40-4.05, 
p=0.001). Scar independently predicted all-cause (26.4% vs 12.9%; p<0.001) and cardiovascular 
mortality (15.0% vs 4.8%; p<0.001), regardless of intervention (TAVR p=0.002, SAVR p=0.026 
[all-cause mortality]). Every 1% increase in LV myocardial scar burden was associated with 11% 
higher all-cause mortality hazard (HR 1.11; 95%CI: 1.05-1.17; p<0.001) and 8% higher 
cardiovascular mortality hazard (HR 1.08; 95%CI: 1.01-1.17; p<0.001). 
Conclusions—In patients with severe AS, late gadolinium enhancement on cardiovascular MR 
was independently associated with mortality; its presence being associated with a 2-fold higher 
late mortality. 
 
Key Words: Aortic Stenosis; Scar; Mortality; Cardiovascular Magnetic Resonance 
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Clinical Perspective 
 
What is new? 
• In patients with severe aortic stenosis (AS), focal myocardial fibrosis (scar) determined 
by CMR was present in over 50% of patients and was associated with a 2-fold higher late 
mortality. 
• Focal scar (both infarct and non-infarct patterns) was independently associated with all-
cause and cardiovascular mortality after both surgical and transcatheter aortic valve 
replacement.  
 
What are the clinical implications? 
• In severe aortic stenosis, late gadolinium enhancement appears to be a useful biomarker 
of left ventricular remodeling, and its presence is associated with worse long-term 
outcomes following aortic valve intervention.  
• This raises the hypothesis that for some patients, timing of aortic valve intervention may 
be too late once scar has developed, and that randomized trials of earlier intervention are 
now required.   
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Introduction 
Aortic stenosis (AS) is the most common valvular heart disease.1 It is characterized by 
progressive narrowing of the aortic valve and by hypertrophic remodeling of the left ventricular 
(LV) myocardium.2 This process maintains wall stress and cardiac performance for many years 
but ultimately the LV decompensates, heralding the transition to heart failure, symptom 
development and death.3 The treatment for AS is valve replacement, with the aim to reduce both 
symptoms and mortality. 
Current guidelines recommend aortic valve intervention by surgical aortic valve 
replacement (SAVR) or transcatheter aortic valve replacement (TAVR) in symptomatic severe 
AS, or asymptomatic severe AS in the presence of LV dysfunction or exercise invoked 
symptoms.4 However symptoms can be difficult to interpret, especially in the elderly who may 
be less active or have multiple co-morbidities, whilst reduction in ejection fraction is often 
irreversible and associated with increased risk of heart failure and death.5 
Whilst the primary insult is the valve stenosis, the cardiac response to this may be equally 
important. Therefore, there is growing interest in objective and early markers of cardiac 
decompensation. Histological and imaging studies have suggested that focal myocardial fibrosis 
is a key driver in the transition from hypertrophy to heart failure.6-10 Myocardial replacement 
fibrosis (“scar”) can be detected by cardiovascular magnetic resonance (CMR) using the late 
gadolinium enhancement (LGE) technique. From single-center studies, focal fibrosis has been 
associated with increased levels of myocardial injury, diastolic and systolic dysfunction, EKG 
changes, and adverse clinical outcomes.7-10 Focal scar by LGE is irreversible at 9 and 12 months 
post SAVR.5, 11 CMR-detected myocardial fibrosis therefore appears to be a useful and objective 
biomarker of LV decompensation in aortic stenosis.  
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Prior studies have been too small to evaluate the independent association of imaging 
biomarkers and demographic factors with total and cardiovascular mortality in patients with 
severe AS.7-10 We established a UK consortium to determine which pre-operative factors were 
most strongly associated with long-term post-operative mortality in patients with severe AS on 
conventional management pathways, which could potentially be used to time surgery better in 
the future. We hypothesized that myocardial scarring detected by LGE-CMR would be 
independently associated with mortality in patients with severe AS undergoing aortic valve 
intervention. 
 
Methods  
The data, analytic methods, and study materials will be made available to other researchers for 
purposes of reproducing the results or replicating the procedure. The data are available from the 
corresponding author on reasonable request.  
Patients and Study Design 
A longitudinal, observational outcome study in patients with severe AS referred to six UK 
cardiothoracic surgical centers and listed for valve intervention (Brompton Hospital and Barts 
Heart Centre in London; Edinburgh Heart Centre; Glenfield Hospital in Leicester; Leeds 
Teaching Hospitals NHS Trust; John Radcliffe Hospital in Oxford). Between January 2003 and 
May 2015, patients were prospectively recruited after evaluation by the multi-disciplinary heart 
team. The study was approved by the UK National Research Ethics Service (13/NW/0832), 
conformed to the principles of the Helsinki Declaration, and all patients gave written informed 
consent. The primary endpoint was all-cause mortality. The secondary endpoint was 
cardiovascular disease-related mortality, as defined by diagnosis on the UK death certificate. 
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Inclusion criteria were patients >18 years with severe AS (one of: aortic valve area 
[AVA]<1cm2, peak pressure gradient >64mmHg, mean pressure gradient >40mmHg, peak 
velocity >4m/s) who had undergone CMR imaging for research purposes.  
Image Acquisition 
Echocardiographic parameters were acquired as part of the clinical work-up following the 
guidelines for assessment of AS severity recommended by the American and European Societies 
of Echocardiography.12 Global hemodynamic load was measured by calculating the valvulo-
arterial impedance index (Zva), defined as the ratio of the estimated LV systolic pressure (sum of 
systolic arterial pressure and mean pressure gradient) to the stroke volume indexed for body 
surface area. CMR was performed on 1.5 Tesla (T) and 3T scanners using standardized 
protocols. In brief, cine images were acquired in long-axis planes and contiguous short-axis 
slices for ventricular volumes, mass and function. Phase-contrast velocity-encoded images were 
acquired for valve hemodynamics and the LGE technique was used to identify myocardial scar, 
as previously described.13 All participating centers have previously published single-center 
mechanistic data in AS, where image quality and specific CMR pulse sequence parameters can 
be reviewed.10, 14-17   
Data Management and Outcomes 
Anonymized clinical and imaging (DICOM) data were collected and managed using REDCap 
(Research Electronic Data Capture) software18 hosted at Barts Heart Centre/University College 
London. All deaths were identified through the UK National Health Service National Spine 
Database. Cardiovascular mortality was established in all deceased from the official death 
certificates, which in the UK list up to 3 causes of death, and were adjudicated by two readers 
(BP, JPG) blinded to all clinical data. Cardiovascular mortality was defined as death attributable 
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to myocardial ischemia and infarction, heart failure, cardiac arrest because of arrhythmia or 
unknown cause, or cerebrovascular accident. 
Data Analysis 
All CMR scans were centralized and re-reported in core-lab fashion by experienced readers 
blinded to clinical parameters using CVI42 software (Circle Calgary, Canada). Each center 
analyzed a single component of the CMR scan for the entire study population, according to a 
pre-specified standard operating procedure (see supplement), and after a period of training and 
reproducibility evaluation. LV volume and mass analysis was performed by manual contouring 
of the endo- and epicardial borders at end-diastole and end-systole.19 Left atrial area and length 
at end-systole were measured in the horizontal (4-chamber) and vertical long axis (2-chamber) 
views for calculation of left atrial volumes by the biplane area length method and indexed.19 
Aortic flow for regurgitant volume and fraction was quantified from phase-contrast velocity-
encoded images.20 LGE was categorized by two observers into three patterns (none, infarct or 
non-infarct patterns) and quantified using the full-width-at-half-maximum method as percentage 
of the LV.13 Examples of typical echocardiographic and CMR images can be seen in Figure 1. 
Further technical details of the image analysis can be found in the supplement.  
Statistics 
Statistical analysis was performed in R (version 3.0.1; The R Foundation for Statistical 
Computing). Distribution of data was assessed on histograms and using Shapiro-Wilk test. 
Continuous variables are expressed as mean ± 1 standard deviation or as median and interquartile 
range; categorical variables, as counts and percent. Baseline characteristics of participants were 
compared using the unpaired Student t-test, Mann-Whitney-Wilcoxon test, χ2 or Fisher exact 
tests as appropriate. The primary endpoint was all-cause mortality. The secondary endpoint was 
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cardiovascular disease related mortality. Additionally, we computed early post-intervention 
(TAVR/SAVR) mortality (defined as 30-day or in-hospital mortality). Survival in patients with 
and without LGE was evaluated using the Kaplan-Meier method and compared among groups 
using the log-rank test. The index date was the date of CMR. Hazard ratios (HR) were expressed 
as mean ± 95% confidence intervals (CI).  
 All clinical parameters were proposed for inclusion in a univariate Cox proportional 
hazards model. The most predictive candidate variable was selected from each of three domains 
if applicable (clinical, echocardiography, CMR) to avoid co-linearity and then entered into the 
final model. Unique, clinically relevant predictor variables with a p value <0.10 in univariate 
analysis were entered into final multivariable models; a forward stepwise procedure was used. 
The incremental value between steps was measured by the χ2 method. The proportional hazards 
assumption was tested with the use of log-log plots and examination of Schoenfeld residuals. All 
tests were 2 sided; p<0.05 was considered significant.  
Role of the funding source 
No additional funding was obtained for this consortium study beyond that of the original single-
center research funding. Funders provided financial support for the original data collection, but 
had no role in the consortium study design, data collection, data analysis, data interpretation, or 
writing of the report. All authors had access to the primary data and have final responsibility for 
publication.  
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Results  
Baseline characteristics 
Baseline characteristics of the 674 patients included are shown in Table 1 and Supplementary 
Figure S1 (Study Flow Chart). Mean age was (7514 years, 63% male) with mean AVA 
0.380.14 cm2/m2; mean gradient 4618 mmHg. Median AV regurgitant fraction was 8.0% (IQR 
2.7-17.3%); 16% of patients had at least moderately elevated pulmonary arterial systolic pressure 
(PASP, defined as 30-55mmHg by echocardiography). LV myocardial scar, as assessed by LGE, 
was present in 51% of patients, in a 2:1 ratio between non-infarct (33%) and infarct pattern scar 
(18%).  
Management by surgical replacement versus transcatheter replacement 
Management was SAVR (n=399) or TAVR (n=275). Median time from CMR to SAVR was 44 
days (IQR 11–103 days), and to TAVR was 13 days (IQR 1–61 days). Compared to SAVR, 
patients managed with TAVR were older (79.2±7.8 vs 68.6±10.3 years, p<0.001), more likely 
female (48% vs 29%, p<0.001), with more atrial fibrillation (21.1% vs 6.5%, p<0.001) and more 
coronary artery disease (39.3% vs 19.5%, p<0.001), less hypertension (42.6% vs 59.5%, 
p<0.001) and fewer bicuspid aortic valves (5.5% vs 33.8%, p<0.001). TAVR patients had higher 
peak AV gradients and smaller AVA. Furthermore, TAVR patients had larger LV volumes, 
lower left ventricular ejection fraction (LVEF) and had more severe symptoms; LV mass and 
LGE prevalence were not different between groups, although infarct pattern scar was more 
prevalent in TAVR and non-infarct scar in SAVR groups.  
Patient characteristics according to LGE status 
LGE+ve patients were more likely to be male (72.7 vs 54.4%, p<0.001), to have had a previous 
myocardial infarct (17.0% vs 4.0%, p<0.001), had larger indexed LVEDV, higher indexed LV 
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mass, and lower LVEF (all p<0.001) than LGE-ve patients (Table 1). In the SAVR cohort only, 
males also had higher NYHA functional class (p=0.006) and higher systolic blood pressure 
(138.520.5 vs 134.017.8 mmHg, p=0.036). 
Outcome 
During a median 3.6 years follow-up (IQR 2.6-5.9 years), 145 (21.5%) patients died (52 post-
SAVR and 93 post-TAVR). This equated to 52 deaths/1,000 patient years (27 and 104 for SAVR 
and TAVR groups, respectively). A cardiovascular cause of death was ascribed to 70 patients 
(10.4% of whole cohort; 19 post-SAVR [4.8%], 51 post-TAVR [18.5%]). 30-day post-
intervention, overall mortality was 1.8% (n=12), with 1.3% (n=5) for SAVR and 2.5% (n=7) for 
TAVR, respectively; at 1-year, overall mortality was 6.2% (n=42), with 3.0% (n=12) for SAVR 
and 10.9% (n=30) for TAVR (Supplemental Table S1).  
Predictors of Outcome 
52 variables were compared to outcome (including demographic, comorbidities, therapies, STS 
score, and imaging [echocardiography/CMR] parameters). At univariate analysis (Tables 2, S2 
and S3 for all, SAVR and TAVR, respectively), 28 of these were associated with outcome. At 
multivariable analysis (Tables 3, S4 and S5 for all, SAVR and TAVR, respectively), the factors 
independently associated with all-cause mortality were age (HR 1.50, 95%CI: 1.11-2.04, 
p=0.009; scaled by epochs of 10 years), STS score (HR 1.12, 95%CI 1.03-1.22, p=0.007) and 
scar presence (HR 2.39, 95%CI 1.40-4.05, p=0.001). The incremental effect of adding age, STS 
score and LGE presence to the risk stratification model is demonstrated in Figure S2; global 
Wald χ2 are shown for separate Cox regression models predicting all-cause death. For 
cardiovascular mortality the factors independently associated with all-cause mortality were age 
(HR 1.94, 95%CI 1.44-2.60, p<0.0001; scaled by epochs of 10 years), female sex (HR 2.17, 
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95%CI 1.28-3.70, p<0.001), LGE presence (HR 3.14, 95%CI 1.65-5.99, <0.001), and reduced 
LVEF (HR 0.98, 95%CI 0.96-1.00, p=0.013). Pulmonary artery systolic pressure (PASP) was 
not included in the main model because data was only available in 63.3% (SAVR 82.7%, TAVR 
49.5%), but when included, presence of severely elevated PASP (PASP>55mmHg) was an 
independent predictor of all-cause mortality (HR 2.73, 95%CI 1.21-6.17, p=0.016; Table S6). 
Neither coronary artery disease nor previous coronary revascularization (PCI or CABG) were 
independent predictors of mortality (Table S7). Furthermore, no echocardiographic or CMR 
markers of AV stenosis severity were independently predictive of mortality. 
 Patients with myocardial scar had higher (double) the all-cause (26.4% vs 12.9%; 
p<0.001) and three times the cardiovascular mortality (15.0% vs 4.8%; p<0.001).  This was 
regardless of valve intervention type (TAVR p=0.002, SAVR p=0.026, Figure 2) and scar type, 
with both infarct and non-infarct scar being associated with similarly adverse outcomes (p<0.001 
for both; see Figure 3) – example: all-cause mortality 25.2% non-infarct pattern LGE, 28.6% 
infarct pattern and 12.9% no LGE. Quantitatively, every 1% increase in LV myocardial scar 
burden was associated with 11% higher all-cause mortality hazard (HR 1.11; 95%CI: 1.05-1.17; 
p<0.001) and 8% higher cardiovascular mortality hazard (HR 1.08; 95%CI: 1.01-1.17; p<0.001, 
Table S8). There was no significant change in results when events within 30 days of intervention 
were excluded or the index date was changed from time of CMR to time of intervention (Table 
S9 and S10). 
 
Discussion 
In patients with severe AS, in terms of disease-based parameters, we have shown that myocardial 
fibrosis (scar) is independently associated with mortality. This was the case for all-cause and 
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cardiovascular mortality, after both surgical and transcatheter intervention, and for both infarct 
and non-infarct scar patterns. Specifically, every 1% increase in scar burden increased mortality 
hazard by 11% and cardiovascular mortality hazard by 8%. Given that most of this scar is AS 
related, and that scar was present in half of the patients, we postulate that for many patients, AS 
surgery is potentially occurring too late, and leaving patients with residual risk.  
AS is important, being the most common valvular heart disease in the developed world 
(>3% of those over 75 years), and the advent of TAVR now offers a treatment option for many 
of those with significant co-morbidities who were previously deemed inoperable. Current 
guidelines recommend valve intervention to improve survival and symptom status when AS is 
severe and ventricular decompensation is present, suggested by the onset of symptoms or 
reduction in LVEF.4 Importantly, we have highlighted in this study an additional component of 
this risk-benefit analysis that has been under-recognized: that is silent irreversible scar is very 
common and is associated with increased mortality. Moreover, the greater the scar burden, the 
higher the mortality. Previous studies have suggested that operating earlier may be beneficial for 
patients, but identifying which patients are likely to benefit is difficult given that many will 
remain asymptomatic for years. Our findings suggest that scar burden might be used to optimize 
the timing of surgical intervention, with half of patients demonstrating irreversible scar, and a 
consequent doubling of post-operative medium-term mortality. Non-infarct pattern scar was 
twice as prevalent as infarct scar, and both predicted worse outcome as previously suggested.8, 9 
In asymptomatic severe AS, the risks of early surgery (1-2% mortality) and prolonged risk of 
prosthesis-associated complications (e.g. endocarditis, pacemaker dependency, bleeding, 
thrombosis, valve degeneration) need to be balanced against the “silent” risk of sudden cardiac 
death (1.5%/year), and increased risk of intervention and long term outcome after symptoms 
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have developed.21 Our results may therefore provide a mechanism for a better selection of 
appropriate patients for early surgery, but this remains to be tested. 
Potential pathophysiology of scar formation 
The ventricle in AS initially responds to pressure-loading by left ventricular hypertrophy 
resulting in adaptive LV remodeling to maintain wall stress and cardiac performance. Despite 
compensatory capillary vasodilatation, over time myocardial oxygen demand outstrips supply 
leading to subendocardial ischemia and eventually LV decompensation.22-24 The transition to LV 
decompensation occurs by fibrosis and myocyte degeneration with irreversible cell loss, mainly 
by autophagy and oncosis.6 This process is driven by subendocardial ischemia and preceded by 
two phenomena: perfusion defects and troponin elevation (indicating myocardial cell death).25, 26 
Replacement fibrosis ensues which starts in the subendocardial layers first and then over time 
affects deeper myocardial layers,17 and in turn contributes significantly to the progression of LV 
systolic dysfunction.6 Diffuse myocardial fibrosis, with increased collagen I and III deposition 
around cardiomyocytes and bundles, occurs predominantly in the mid-myocardium.17 Patchy foci 
of fibrosis on LGE imaging can be indicative of widespread diffuse fibrosis. Diffuse fibrosis can 
be assessed by CMR T1 mapping,17, 27 but was not investigated in this study, as it has only 
become available more recently.   
Focal fibrosis identified by LGE is associated with adverse outcome across a wide range 
of myocardial pathologies,28 and has been shown in small single center studies to be associated 
with outcome in AS.7-10 The presented data place LGE-detected scar firmly as a key outcome 
predictor in AS and suggest that current timing of valve intervention (TAVR or SAVR), based 
on a combination of valve severity and symptoms, may be too late for optimal long-term 
outcomes. This was highlighted in a recently completed multi-center observational study in 
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asymptomatic patients with moderate-severe AS (PRIMID-AS; NCT01658345), the presence of 
scar on LGE did not predict symptom onset.14 
Earlier intervention, for example in asymptomatic severe AS may therefore warrant 
investigation. Despite numerous observational studies to assess risk prediction in asymptomatic 
AS there have been no randomized trials of early intervention to improve outcome. Patients at 
risk of myocardial decompensation due to scar, or myocardium in the process of developing scar, 
can be identified early through the use of hs-Troponin, perfusion defects or CMR LGE 
techniques.15 One study that will go some way to address this issue is EVOLVED-AS 
(NCT03094143), a parallel-group, multicenter, prospective randomized trial (open-label blinded 
endpoint) of early aortic valve intervention in asymptomatic patients with severe AS and 
evidence of LV decompensation, as evidenced by non-infarct pattern LGE. In the absence of 
prospective randomized trials, only registry data suggest the likely impact of early surgery.29, 30  
Stratifying intervention based on the presence of LGE may be too late, since even the 
small amount of scar detected in our cohort, is associated with residual increased risk of all-cause 
and cardiovascular mortality, but until EVOLVED-AS and further studies report, the role, timing 
and intervals for CMR to guide decision making in patients with moderate-to-severe AS remain 
unclear. 
Our study has limitations. This was an observational study of patients at surgical centers 
with an interest in CMR and echocardiography for clinical and research indications, potentially 
introducing selection bias. Due to the contra-indications for contrast enhanced CMR, patients 
with severe renal impairment and pre-operative pacemaker/defibrillators were not represented. 
Sixty-one patients did not undergo LGE imaging. There were no reported invasive measures of 
hemodynamics (during angiography), hematocrit, brain natriuretic peptides or blood troponin; as 
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per clinical routine renal function was checked prior to LGE CMR, but was not systematically 
captured or easily retrieved for this analysis. Furthermore, no routine imaging follow-up was 
performed. Although studies of other populations have shown that unrecognized infarct scar 
increases with age,31 and can be found in up to 10% of subjects, this would only account for 
minority of the scar burden found in our population. Both TAVR and SAVR have been 
associated with de-novo LGE, which may be associated with further myocardial 
decompensation.32, 33 Due to the lack of follow-up CMR data, the possibility of further peri-
procedural damage could not be excluded. Finally, multivariate analysis was not controlled for 
the type of intervention, in particular this may have been important in TAVR where the learning 
curve and patient selection has changed over the years. 
Conclusion  
In patients with severe AS, pre-operative focal myocardial scar is independently associated with 
mortality; its presence being associated with a 2-fold higher late mortality. 
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Table 1. Baseline Characteristics  
 
Variable 
All Patients* 
(n=674) 
+LGE 
(n=341)‡ 
–LGE 
(n=272)‡ 
p-value 
Age, years 74.6 | 14.4 74.3 | 14.6 75.0 | 14.5 0.44 
Intervention                              SAVR† 399 (59.2) 194 (56.9) 176 (64.7)  
0.05 
 
                                                 TAVR 275 (40.8) 147 (43.1) 96 (35.3) 
Male, No. (%) 425 (63) 248 (72.7) 148 (54.4) <0.001 
BMI, Kg/m2 27.6 ± 5.1 27.8 ± 5.1 27.3 ± 4.8 0.20 
Atrial Fibrillation, No. (%) 84 (12.5) 49 (14.4) 28 (10.3) 0.13 
Diabetes Mellitus, No. (%) 146 (21.7) 77 (22.6) 58 (21.3) 0.71 
Hypertension, No. (%) 358 (53.1) 184 (54.0) 155 (57.0) 0.46 
Systolic BP, mmHg 135.0 ± 20.4 133.4 ±20.3 137.3 ± 20.2 0.03 
Diastolic BP, mmHg 72.7 ± 12.2 72.2 ± 11.8 74.0 ± 11.8 0.10 
Bicuspid Aortic Valve, No. (%)§ 149 (22.1) 80 (23.5) 53 (19.4) 0.23 
Known CAD, No. (%)  197 (29.2) 123 (36.1) 74 (27.2) 0.16 
No previous PCI/CABG, No. (%)§   533 (79.1) 260 (76.2) 220 (80.9) 0.65 
Previous PCI, No. (%) 57 (8.5) 38 (11.1) 16 (5.9) 0.07 
Previous CABG, No. (%) 58 (8.6) 31 (9.1) 22 (8.1) 0.92 
History of MI, No. (%)§ 73 (10.8) 58 (17.0) 11 (4.0) <0.001 
STS Mortality Risk score, % 1.75 | 1.89 1.74 | 1.79 1.76 | 1.69 0.78 
EuroSCORE II, % 1.81 | 2.4 1.87 | 2.85 1.64 | 1.69 0.07 
NYHA Functional Class, No. (%)§         
I 81 (12.0) 33 (9.7) 47 (17.3) 
0.03 
II 258 (38.3) 138 (40.5) 90 (33.1) 
III 248 (36.8) 127 (37.2) 98 (36.0) 
IV 22 (3.3) 10 (2.9) 8 (2.9) 
Baseline Medications, No. (%)§         
  ACE inhibitor or ARB 262 (38.9) 139 (40.8) 107 (39.3) 0.56 
  β-blocker 240 (35.6) 130 (38.1) 92 (33.8) 0.27 
  Aldosterone Antagonist* 36 (5.3) 21 (61.6) 11 (4.0) 0.12 
  Statin 406 (60.2) 224 (65.7) 162 (59.6) 0.23 
Echocardiographic data         
  Mean aortic valve gradient, mmHg 46.0 | 18.0 46.0 | 19.0 46.0 | 17.0 0.20 
  Peak aortic valve gradient, mmHg 78.0 | 30.0 78.0 | 30.0 79.5 | 30.0 0.34 
  AVA, cm2 0.70 | 0.31 0.70 | 0.21 0.70 | 0.17 0.98 
  Indexed AVA [to BSA], cm2/m2 0.38 | 0.14 0.41 | 0.13  0.40 | 0.13 0.94 
Estimated PASP, No. (%)§       Normal 316 (46.9) 159 (46.6) 138 (50.7) 
0.85 Moderate (31-55mmHg) 80 (11.9) 43 (12.6 30 (11.0) 
                       Severe (>55mmHg) 30 (4.5) 16 (4.7) 11 (4.0) 
CMR data          
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LV end diastolic volume index, mL/m2 79.5 | 29.3 85.4 | 33.4 73.3 | 23.1 <0.001 
LV stroke volume index, mL/m2 46.2 | 14.5 46.0 | 14.9 45.8 | 14.2 0.80 
LV Ejection Fraction, % 61.0 | 16.7 58.0 | 21.0 64.0 | 12.0 <0.001 
Maximal LV wall thickness, mm 14.0 | 4.0 14.0 | 4.0 13.0 | 3.0 <0.001 
LV mass index, g/m2 81.0 | 31.0 87.1 | 31.3 74.9 | 28.5 <0.001 
RV end diastolic volume index, mL/m2 67.4 | 22.2 68.5 | 22.5 66.8 | 19.8 0.015 
RV ejection fraction, % 65.0 | 13.0 63.8 | 15.0 65.0 | 11.0 0.026 
Indexed left atrial volume, mL/m2 52.8 | 25.7 53.3 | 24.4 51.4 | 25.4 0.19 
CMR AoV regurgitant fraction, % 8.0 | 14.7 8.9 | 16.2 7.7 | 12.2 0.12 
Valvulo-Arterial Impedance 3.93 | 1.4 3.93 | 1.3 3.98 | 1.5 0.20 
LGE present, No. (%) 341 (50.6) 341 (100) 0 / 
  Non-infarct-pattern, No. (%) 222 (32.9) 222 (65.1) 0 / 
  Infarct-pattern, No. (%) 119 (17.7) 119 (34.9) 0 / 
LGE mass, %  0.53|| | 3.08 2.72 | 3.95 0 / 
Normally distributed continuous variables are expressed as mean ± standard deviation; nonparametric 
continuous variables are expresssed as median | interquartile range; categorical variables are expressed as 
counts (percent). 
* refers to all patient groups: all SAVR + TAVR; † refers to all SAVR: i.e. SAVR+SAVR/CABG 
‡ For the LGE columns 61 subjects (32 TAVR and 29 SAVR) did not undergo late gadolinium 
enhancement imaging. 
§ denotes that this variable of counts contains missing data, e.g. 46 missing in NYHA (incomplete data); 
5 missing bicuspid AV data points; 26 baseline CAD missing data points; 1 missing MI data point.  
|| LGE mass (in %) as the median of all patients including those without LGE.  
Abbreviations:  ARB, angiotensin receptor blocker; AVA, aortic valve area; BMI, body mass index; BP, 
blood pressure; CABG, coronary artery bypass grafting; CAD, coronary artery disease; LGE, late 
gadolinium enhancement; LV, left ventricle; MI, myocardial infarction; No., numbers; PASP, pulmonary 
artery systolic pressure; PCI, percutaneous coronary intervention; RV, right ventricle; SAVR, surgical 
aortic valve replacement; TAVR, transcatheter aortic valve replacement.
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Table 2. Univariate Parameters  
 
Parameter ALL PATIENTS (n=674) ALL PATIENTS (n=674) 
 All Cause Mortality (n=145) Cardiovascular Mortality (n=70) 
 HR Z P value 95% CI HR Z P value 95% CI 
Baseline Demographics         
Age* 1.92 7.04 <0.0001 1.60 – 2.31 2.24 5.75 <0.0001 1.70 – 2.95 
Male Sex 0.77 -1.58 0.115 0.55 - 1.07 0.55 -2.47 0.014 0.35 - 0.88 
BMI 0.98 -1.40 0.161 0.94 - 1.01 0.97 -1.21 0.227 0.92 - 1.02 
Atrial Fibrillation 2.33 4.202 <0.001 1.57 – 3.45 3.37 4.57 <0.0001 2.01 – 5.67 
Diabetes Mellitus 1.32 1.48 0.139 0.91 - 1.90 1.93 2.63 0.009 1.18 – 3.14 
Hypertension 1.06 0.37 0.715 0.77 - 1.47 1.02 0.08 0.940 0.64 - 1.63 
Bicuspid AoV 0.28 -4.43 <0.0001 0.16 - 0.50 0.25 -3.23 0.001 0.11 - 0.58 
Previous CAD  1.69 3.02 0.003 1.20 - 2.38 1.98 2.77 0.006 1.22 – 3.20 
Previous PCI or CABG 1.51 2.09 0.037 1.03 - 2.24 1.82 2.17 0.030 1.06 – 3.11 
Previous MI 0.74 -1.17 0.244 0.44 - 1.23 0.67 -1.10 0.271 0.33 -1.36 
Baseline NYHA Functional Class         
II 2.70 2.12 0.034 1.08  - 6.80 2.82 1.39 0.163 0.66 – 12.17 
III 4.16 3.05 0.002 1.66 – 10.40 5.60 2.35 0.019 1.33 – 23.52 
IV 8.75 4.01 <0.0001 3.03 – 25.21 15.28 3.40 <0.001 3.17 – 73.67 
Baseline Medications 
ACE inhibitor or ARB 1.37 1.78 0.076 0.97 - 1.94 1.50 1.61 0.107 0.92 - 2.44 
β-blocker 1.19 1.04 0.300 0.85 - 1.67 1.45 1.53 0.127 0.90 - 2.32 
Aldosterone Antagonist 0.82 -0.52 0.607 0.38 – 1.76 1.44 0.85 0.398 0.62 – 3.34 
Statin 1.16 0.83 0.408 0.82 - 1.65 1.30 1.01 0.314 0.78 – 2.15 
STS score 1.18 7.78 <0.0001 1.13 - 1.23 1.22 7.15 <0.0001 1.15 - 1.28 
Euroscore 1.10 5.20 <0.0001 1.06 - 1.13 1.12 5.35 <0.0001 1.08 - 1.17 
Echo Data         
Mean AoV gradient  1.00 0.84 0.402 0.99 – 1.02 0.99 -0.66 0.509 0.97 - 1.01 
Peak AoV gradient 1.00 0.83 0.407 1.00 - 1.01 1.00 -0.33 0.740 0.99 - 1.01 
AoV area 0.33 -2.30 0.021 0.13 - 0.85 0.23 -2.05 0.040 0.06 - 0.94 
AoV area Indexed to BSA 0.30 -1.36 0.173 0.05 - 1.70 0.26 -1.03 0.301 0.02 – 3.32 
Estimated PA pressure         
Moderate  2.10 2.73 0.006 1.23 - 3.58 3.07 2.86 0.004 1.42 - 6.63 
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Severe 4.09 3.98 <0.0001 2.04 – 8.20 7.10 4.28 <0.0001 2.90 - 17.41 
CMR data         
LV end diastolic volume index 1.00 1.17 0.242 1.00 - 1.01 1.00 0.91 0.366 1.00 - 1.01 
Indexed LV Stroke Volume 0.97 -4.27 <0.0001 0.95 - 0.98 0.96 -4.11 <0.0001 0.94 - 0.98 
LV Ejection Fraction 0.98 -4.87 <0.0001 0.97 - 0.99 0.97 -5.06 <0.0001 0.95 - 0.98 
Maximal LV wall thickness 0.93 -2.45 0.014 0.88 - 0.99 0.91 -2.22 0.026 0.84 - 0.99 
Indexed LV mass 1.00 -0.29 0.769 0.99 - 1.01 1.00 -0.24 0.811 0.99 - 1.01 
RV end diastolic volume index 1.00 -0.48 0.628 0.99 - 1.01 1.00 -0.15 0.878 0.98 - 1.01 
RV Ejection Fraction 0.98 -3.29 0.001 0.96 - 0.99 0.96 -3.68 0.002 0.95 - 0.98 
Indexed LA volume 1.01 3.17 0.002 1.00 - 1.02 1.02 3.66 <0.001 1.01 - 1.03 
CMR AoV regurgitant fraction 0.99 -0.82 0.412 0.98 - 1.01 0.98 -1.32 0.186 0.96 - 1.01 
Valvulo-Arterial Impedance 1.17 1.93 0.054 1.00 - 1.37 1.21 1.62 0.106 0.96- 1.51 
Late gadolinium enhacement (LGE) 
LGE presence / absence 2.22 4.00 <0.0001 1.50 - 3.28 3.38 3.92 <0.0001 1.84 – 6.22 
LGE pattern         
Non-infarct 2.08 3.40 <0.001 1.36 - 3.17 2.80 3.06 0.002 1.45 – 5.40 
Infarct 2.49 3.79 <0.001 1.55 - 4.00 4.54 4.36 <0.0001 2.30 – 8.97 
LGE mass, per 1% increase 1.07 4.00 <0.0001 1.04 - 1.11 1.09 3.78 <0.001 1.04 - 1.13 
*Using age variable scaled by epochs of 10. 
Abbreviations: BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; PCI, percutaneous coronary intervention; CABG, 
coronary artery bypass grafting; MI, myocardial infarction; ARB, angiotensin receptor blocker; AVA, aortic valve area; PASP, pulmonary artery 
systolic pressure, LV, left ventricle; RV, right ventricle; LGE, late gadolinium enhancement.   
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Table 3. Multi-Variable Model – All Cause and Cardiovascular Mortality  
 
 ALL PATIENTS (n=674) 
ALL CAUSE MORTALITY (n= 145) 
Parameter HR Z P value 95% CI Chisq (P value) 
CMR RV ejection fraction 1.01 0.89 0.374 0.99 – 1.04 –862.7 / 
CMR LV ejection fraction 1.00 –0.15 0.879 0.98 – 1.02 12.5 (<0.001) 
CMR BSA-Indexed LA Volume 1.00 0.64 0.520 0.99 – 1.02 140.4 (<0.0001) 
Atrial fibrillation 1.39 0.87 0.383 0.66 – 2.92 7.3 (0.007) 
LV maximal wall thickness 0.93 –1.85 0.064 0.85 – 1.01 4.6 (0.032) 
STS Score 1.12 2.68 0.007 1.03 – 1.22 38.8 (<0.0001) 
CMR BSA-Indexed LV SV 1.00 –0.21 0.832 0.97 – 1.02 3.9 (0.050) 
CAD 0.99 –0.05 0.963 0.59 – 1.65 11.3 (<0.001) 
AVA (by echo) 1.10 0.18 0.855 0.39 – 3.12 571.6 (<0.0001) 
Age* 1.50 2.61 0.009 1.11 – 2.04 5.0 (0.026) 
LGE Presence 2.39 3.22 0.001 1.40 – 4.05 129.7 (<0.0001) 
Bicuspid AV 0.67 –1.01 0.315 0.31 – 1.46 1.95 (0.163) 
 ALL PATIENTS (n=674) 
CV ONLY MORTALITY (n= 70) 
Parameter HR Z P value 95% CI Chisq (P value) 
Female Sex 2.17 –2.89 0.004 1.28 – 3.70 -89.4 / 
Previous CAD 1.53 1.60 0.110 0.91 – 2.56 28.0 (<0.0001) 
CMR LV EF 0.98 –2.50 0.013 0.97 – 1.00 22.8 (<0.0001) 
Atrial Fibrillation 1.43 1.17 0.240 0.79 – 2.58 8.2 (0.004) 
Age* 1.94 4.41 <0.0001 1.44 - 2.60  21.3 (<0.0001) 
LGE Presence 3.14 3.47 <0.001 1.65 – 5.99 82.2 (<0.0001) 
*Using age variable scaled by epochs of 10. 
Abbreviations: AVA, aortic valve area; BSA, body surface area, CAD, coronary artery disease; LA, left 
atrium, LGE, late gadolinium enhancement; LV, left ventricle, SV, stroke volume.   
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Figure Legends 
 
Figure 1. Multi-modality Assessment of Aortic Stenosis.  
Assessment of aortic stenosis (AS) by transthoracic echocardiography (TTE, A-C) and 
cardiovascular magnetic resonance (D-F). A. Continuous Doppler trace across the aortic valve in 
the apical 5-chamber demonstrating hemodynamic parameters consistent with severe AS (peak 
velocity 4·67m/s, peak gradient of 87mmHg and mean gradient 51mmHg). B. Short axis TTE 
image of a severely calcified aortic valve. C. Parasternal long axis image demonstrating left 
ventricular hypertrophy (#) and a calcified aortic valve (*). D. Four chamber balanced SSFP cine 
image demonstrating left ventricular hypertrophy; the white dotted line demonstrates the axis of 
acquisition of the short axis (E+F). E. Late gadolinium enhancement (LGE) image in a mid-
ventricular short axis showing transmural LGE of a full-thickness myocardial infarct (arrow). F. 
LGE image in a mid-ventricular short axis showing patchy non-ischemia LGE in the mid 
inferolateral segment (arrow) as well as more subtle LGE in the inferoseptum and right 
ventricular insertion points.  
 
Figure 2. All-Cause and cardiovascular mortality in severe AS by LGE status.  
Kaplan Meier survival plots showing all-cause (left) and cardiovascular (right) mortality in: all 
patients (A and B, n=674); patients treated with surgical aortic valve replacement (C and D, 
n=399); and patients treated with transcatheter aortic valve replacement (E and F, n=275), 
according to the presence or absence of late gadolinium enhancement (LGE) pre-operatively.  
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Figure 3. All-Cause mortality in severe AS by LGE pattern. 
Kaplan Meier survival plot showing all-cause mortality in all patient with severe aortic stenosis 
(n=674) by pattern of late gadolinium enhancement (no LGE, infarct LGE, non-infarct LGE; 
both p<0.001). The plot is summarizing 6-year follow-up data. 
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1. Figure S1: Study Diagram 
 
 
 
 
Figure S1: BSCMR AS700 Flow Diagram.  
A longitudinal, observational outcome study in patients with severe AS referred to six UK 
cardiothoracic surgical centres and listed for valve intervention. Between January 2003 and May 
2015, patients were prospectively recruited after evaluation by the multi-disciplinary heart team. 
Inclusion criteria were patients >18 years with severe AS (one of: aortic valve area [AVA]<1cm2, 
peak pressure gradient >64mmHg, mean pressure gradient >40mmHg, peak velocity >4m/s) who 
had undergone CMR imaging for clinical or research purposes.  
AVA, aortic valve area; CMR, cardiovascular magnetic resonance; SAVR, surgical aortic valve 
replacement; TAVR, transcatheter aortic valve replacement; RBH, Royal Brompton Hospital; UCL, 
University College London.  
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2. Figure S2: Incremental Risk Stratification 
To demonstrate the sequence in which information becomes clinically available for risk 
stratification, the global Wald χ2 are shown for separate Cox regression models predicting all-
cause death, showing how the successive addition of volumetric indices, clinical variables, STS 
score and LGE significantly increase the global Wald χ2 (probability values attributable to the 
addition of the new variable are also shown accounting for the variables already present in the 
model). 
 
 
AF, atrial fibrillation; AVA, aortic valve area; BAV, bicuspid aortic valve; CAD, coronary 
artery disease; CMR, cardiovascular magnetic resonance; EF, ejection fraction; LGE, late 
gadolinium enhancement; LA, left atrium; LV, left ventricle; MWT, maximal wall thickness; 
STS, Society of Thoracic Surgery score; SV, stroke volume; Vol, volume. 
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3. Pre-specified Standard Operating Procedure for Data Analysis 
 
Data analysis was pre-specified in a standard operating procedure document (SOP). This SOP 
ensured a consistent approach in respect of image analysis across the six sites. The analysis was 
performed in a distributed core-lab approach. All patients were uploaded as anonymised scans to a 
central repository. Each centre analysed a specific domain across the whole cohort (Figures in this 
section are not referred to in the main manuscript). 
 
Standard Operating Procedure – BSCMR Valve Consortium 
3.1 Circle Cardiovascular Imaging cvi42: Housekeeping  
1) The same version of the CVI42 is utilised across the 6 sites (Version 5.1.2, Calgary, Canada). 
This, in particular, is important for those sites designated LV and RV chamber quantification. There 
are obvious differences in dashboard aesthetics and “smoothness” of contouring tools and it would 
be optimal for analysis to be performed on the same software. 
 
2) To use a pre-specified zoom ‘%’ of x2.0 or x2.7 for the workspace prior to contouring. 
 
3) To use the pre-defined cvi windowing setting of 3 (although custom windowing should 
obviously be used if this setting is of suboptimal image quality) 
 
4) Manual contouring of the LV and RV is performed using the bezier tool (‘click-draw’ icon 
displayed, see below).  
 
 
5) To employ the following cvi42-specific SOP for standardising backend contour settings: 
 
SubPixel Matrix size = 4X4 
Signal Intensity SD = use subpixel weighted SD (and not biased SD) 
Contour detection = check contour detection connect to view 
Rounded SAX endocardial contour = leave inactive 
Papillary muscle detection = check this  
SAX chord generation = uncheck this 
 
6) The contours drawn are saved locally  
- “save workspace DICOM” via workspace option on task bar 
- return to patient list view  
- and choose “extended view” option at bottom left of screen 
- select patient under study 
- scroll down to end of sequence list and select the saved DICOM workspace 
- right click on this and “export series” 
- save in a designated folder on local drive 
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- upload contour workspace straight into the research participant's REDCap module 
using 'File Upload' option 
 
7) Similarly, that derived values (e.g. absolute LVEDV, LV mass etc) are manually entered into the 
CMR variables section of the BSCMR project in RedCAP under the patient being studied. 
 
 
3.2 Left Atrial Volume Quantification 
 
- Measurement of left atrial (LA) volume is by the biplane area–length method.  
- Images are analysed in the viewer module of cvi42 with a dual panel display selected to permit 
synchronisation of HLA and VLA by phase. 
- All measurements are taken from the two-chamber (A) and four-chamber (B) views at end-
ventricular systole, ensuring maximal LA size.  
- The atrial endocardial border is traced to determine LA area with exclusion of the pulmonary 
veins, LA appendage, and mitral valve recess.  
- LA length is measured from the midpoint of the mitral annulus plane to the posterior aspect of 
the left atrium. Left atrial volume (LAV) was calculated using the formula:  
LAV  = 8(A2Ch)(A4Ch) / 3πL 
 
-   where A2Ch and A4Ch refer to the LA area in the two-chamber and four-chamber views, 
respectively, and L is the shorter of the two LA length measurements (L2Ch, L4Ch) from these 
views (see below. 
 
(Adapted from Gulati et al. 2013. European Journal of Heart Failure; 15(6); 660-670). 
 
 
3.3 Left and Right Ventricular Volume and Mass Quantification 
(adapted from Schulz-Menger et al. Journal of Cardiovascular Magnetic Resonance 2013, 15:35) 
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- For each study, LV and RV volumes and LV mass are to be contoured by the same one 
individual.  
- If no intra- or extracardiac shunts are present, the RV and LV stroke volumes should be nearly 
equal (small differences are seen as a result of bronchial artery supply). Since the LV stroke 
volume is more reliably determined than the RV stroke volume, the LV data can be used to 
validate RV data. 
- The dedicated LV short axis cine stack is to be contoured for both LV AND RV quantification. 
- Manual contouring performed in cvi42 using the Bezier tool is the suggested method of 
analysis; the fully automated contour detection option is to be avoided. 
- For the purposes of facilitating consistency of standards across different sites, a control sample 
of 5 cases will all be analysed by each of the three readers quantifying LV and RV parameters. 
These will then be surveyed by the PI to help provide feedback on technique and assist in 
answering any outstanding queries.  
 
 
3.3.1 The Left Ventricle 
 
- The LV end-diastolic and end-systolic image should be chosen as the images with the largest 
and smallest LV blood volumes respectively. (For their identification, the full image stack 
should be evaluated) 
- Deviations may occur and extra care should be taken in the setting of LV dyssynchrony or 
severe mitral regurgitation. Aortic valve closure defines end-systole. 
- If a slice is uninterpretable (e.g. degraded by triggering/breathing artefact) it should be excluded 
from systolic and diastolic measurements of both the LV and RV. 
- The LV outflow tract is included as part of the LV blood volume. When aortic valve cusps are 
identified on the basal slice(s) the contour is drawn to include the outflow tract to the level of 
the aortic valve cusps. 
- Care must be taken with the one or two most basal slices. A slice that contains blood volume at 
end-diastole may include only left atrium (LA) without LV blood volume at end-systole. The 
LA can be identified when less than 50% of the blood volume is surrounded by myocardium 
and the blood volume cavity is seen to be expanding during systole. 
- Papillary muscles are to be EXCLUDED from the LV cavity for the purpose of analysis and 
included within the LV mass (thus DO require specific delineation). 
- Epicardial borders should be drawn on the middle of the chemical shift artifact line (when 
present). 
- Absolute LV mass is derived from diastolic epicardial and endocardial delineation; systolic 
epicardial contours are NOT required. 
- Maximal LV Wall Thickness is measured as the thickest portion of the interventricular septum 
in short axis at end diastole (mm) 
- When the most basal slice contains only a small crescent of basal lateral myocardium and no 
discernible ventricular blood pool, an epicardial contour for the visible myocardium is included 
for LV mass only. 
- Similarly, when the most apical slice contains only a circle of myocardium without cavitary 
blood pool, an epicardial contour without an endocardial contour should be drawn for LV mass 
calculations 
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Left ventricular (LV) chamber quantification. For LV chamber quantification, the endocardial (blue) and 
epicardial (yellow) contours are delineated in diastole in a stack of short axis slices that cover the whole left 
ventricle. c) illustrates the approach with EXclusion of the papillary muscles as part of the LV volume. 
 
 
3.3.2 The Right Ventricle 
 
- As for the LV, it may be necessary to review all image slices in the stack to define end-diastole 
and end-systole for the RV. 
- Trabeculations of the RV are ignored and a smooth endocardial border is drawn to improve 
reader reproducibility (RV trabeculae and papillary muscles are typically included in RV 
volumes). 
- Again, if no intra- or extracardiac shunts are present, the RV and LV stroke volumes should be 
nearly equal (small differences are seen as a result of bronchial artery supply). 
- Since the LV stroke volume is more reliably determined than the RV stroke volume, the LV 
data can be used to validate RV data. 
- The pulmonary valve may be visualized, and contours are included just up to, but not superior 
to this level. 
	 9 
 
 
Right ventricular (RV) chamber quantification. For RV volume quantification, the endocardial (red) 
contours are delineated in diastole (top) and systole (bottom) or short-axis (c and d) slices that cover the 
whole RV. 
 
 
3.4 Aortic Valve haemodynamic assessment from quantification of VENC images 
(adapted from Schulz-Menger et al. Journal of Cardiovascular Magnetic Resonance 2013, 15:35) 
 
- Phase and magnitude images are analysed in the Flow module of cvi42 software. 
- The dedicated aortic valve short axis cine (typically 8 slices) is viewed in the viewer module to 
determine the anatomic aortic valve orifice by 2D valve planimetry in peak systole when the 
opening of the aortic valve is widest. This is done by manually tracing the inner leaflet edges of 
the aortic valve cusps at the time of maximal opening; recording the average of three 
consecutive AVA measurements. 
- Images are windowed to the appropriate brightness and contrast so that the borders of the ROI 
are sharp. 
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- Through-plane phase contrast images are examined to ensure the quality is sufficient and that 
the VENC chosen was appropriate. 
- The borders of the vessel of interest are traced on each phase and magnitude image so that only 
the cavity of the vessel is included ensuring noise outside the vessel is not included 
- Checks are made that this is performed correctly on the magnitude images (as always the phase 
images contain the encoded information) 
- Where a number of phase contrast sequences have been acquired, the highest value for peak 
flow velocity and forward flow volumes should be recorded.  Regurgitant fraction should be 
derived from non breath held images. 
Pitfalls: 
- On the phase images, the area of flow may be slightly larger than the area of the magnitude 
images. 
- If aliased the sequence should be disregarded and another analysed. 
- The use of software correction to analyse aliased images is to be avoided. 
- In general, the area that exceeds the VENC in the ROI is in the centre of the vessel and not at 
the edges; if at the edges, it is usually (but not always) outside the vessel. 
 
3.5 Late Gadolinium Enhancement Quantification 
 
- All images are to be quantified using CVI 42.  
- Manual epi and epdocardial quantification are performed from the dedicated LV volume short 
axis cine stack in end diastole in order to quantify LV mass (papillary muscles were excluded).  
- The short axis LV stack acquired  10-15 minutes following Gadolinium (Doteram 0.2mmol/kg) 
contrast administration is used for the purposes of late gadolinium quantification. 
- Each slice is visually inspected by 2 doctors experienced in MRI analysis for the presence or 
absence of gadolinium enhancement.  
- Phase swap and other geometry images were used in order to assist in decision making where 
required.  
- In only those slices deemed to have LGE present, epi and endocardial contours were manually 
drawn, with care take to exclude artefact, blood pool, fat and pericardium. 
- The auto-identification tool was then applied and an area of normal remote myocardium 
defined alongside identification of areas with increased signal intensity.  
- Any hyperintense regions felt to be related to artefact are manually excluded.  
- The 2SD, 5SD and full width half max techniques are used to determined LGE mass.  
 
NB: There was no significant difference in association of the different LGE quantification 
techniques. Previous reports showed that the FWHM technique was the most reproducible for 
infarct and non-infarct LGE (Flett et al. Circulation Cardiovascular Imaging 2011), thus we chose 
this a priori as the technique for our analysis. 
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4. Supplementary Tables:  
 
4.1 TABLE S1: FOLLOW-UP AND MORTALITY 
 
 
  
 All patients (n = 674) All TAVR 
(n=275) 
All SAVR (n=399) P VALUE 
Follow-up     
Follow-up duration post CMR date (days) 1515 ± 847 1190 ± 692 1740 ± 872 <0.0001 
Mortality     
30-day mortality post intervention (%) 12 (1.8) 7 (2.6) 5 (1.3) 0.570 
1-year mortality post intervention (%) 42 (6.2) 30 (10.9) 12 (3.0) <0.0001 
All – Cause Death, No. post CMR (%) 145 (21.5) 93 (33.8) 52 (13.0) <0.0001 
CV Death, No. post CMR (%) 70 (10.4) 51 (18.5) 19 (4.8) <0.0001 
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4.2 TABLE S2: UNIVARIATE PARAMETERS – Surgical Aortic Valve Replacement. 
 
Abbreviations: SAVR, surgical aortic valve replacement; BMI, body mass index; BP, blood pressure; CAD, coronary 
artery disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MI, myocardial 
infarction; ARB, angiotensin receptor blocker; AVA, aortic valve area; PASP, pulmonary artery systolic pressure, LV, 
left ventricle; RV, right ventricle; LGE, late gadolinium enhancement.   
  
Parameter ALL SAVR (n=399) ALL SAVR (n=399) 
 All Cause Mortality (n=52) Cardiovascular Mortality (n=19) 
 HR Z P value 95% CI HR Z P value 95% CI 
Baseline Demographics         
Age 1.60 3.22 0.001 1.20 – 2.14 1.64 2.01 0.044 1.01 – 2.64 
Male gender 0.99 -0.04 0.966 0.54 - 1.80 0.55 -1.27 0.205 0.22 – 1.38 
BMI 1.02 0.76 0.447 0.97 - 1.08 1.07 1.40 0.163 0.97 – 1.17 
Atrial Fibrillation 2.38 2.24 0.025 1.11 -  5.09 5.03 3.06 0.002 1.79 – 14.15 
Diabetes Mellitus 1.61 1.59 0.112 0.89 -  2.91 2.22 1.67 0.095 0.87 – 5.64 
Hypertension 1.73 1.81 0.070 0.96 - 3.12 1.10 0.20 0.846 0.44 – 2.74 
Bicuspid AoV 0.51 -2.00 0.046 0.27 - 0.99 0.63 -0.90 0.369 0.23 – 1.74 
Previous CAD  1.69 1.71 0.088 0.93  - 3.09 1.89 1.29 0.197 0.72 -  4.98 
Previous PCI or CABG 0.71 -0.66 0.510 0.25 - 1.99 / / 0.998 0 >inf 
Previous MI 0.77 -0.50 0.616 0.28 - 2.15 1.23 0.20 0.842 1.16 – 9.25 
Baseline Medications         
ACE inhibitor or ARB 1.41 1.22 0.223 0.81 -  2.46 1.61 1.03 0.304 0.65 -  3.95 
β-blocker 0.85 -0.53 0.594 0.46 - 1.55 1.48 0.84 0.400 0.59 -  3.69 
Aldosterone Antagonist 0.75 -0.40 0.692 0.17 - 3.19 1.04 0.04 0.971 0.13 -  8.28 
Statin 1.47 1.20 0.231 0.78 -  2.75 2.32 1.49 0.138 0.76 – 7.06 
STS score 1.15 1.74 0.083 0.98 -  1.34 1.19 1.57 0.115 0.96 – 1.48 
Euroscore 1.03 0.57 0.569 0.93 - 1.13 1.04 0.44 0.662 0.88 – 1.22 
Echo Data         
Mean AoV gradient 1.00 -0.12 0.908 0.98 - 1.02 0.99 -0.59 0.553 0.95 – 1.03 
Peak AoV gradient  1.00 0.001 0.999 0.99 - 1.01 0.99 -0.41 0.682 0.97 – 1.02 
AoV area 0.74 -0.45 0.654 0.20 - 2.79 0.26 -1.16 0.247 0.03 – 2.57 
AoV area Indexed to BSA 0.66 -0.32 0.751 0.05 - 8.25 0.08 -1.11 0.269 0.001 - 6.81 
Estimated PA pressure         
Moderate  1.42 0.70 0.487 0.53 - 3.78 1.94 0.81 0.417 0.39 – 9.63 
Severe 5.27 2.67 0.007 1.55 - 17.88 12.8 3.06 0.002 2.50 – 65.90 
CMR data         
LV end diastolic volume index 1.00 -0.28 0.780 0.99 - 1.01 1.00 -0.39 0.696 0.98 – 1.02 
Indexed LV Stroke Volume 0.98 -1.48 0.140 0.96 - 1.01 0.96 -1.96 0.051 0.92 – 1.00 
LV Ejection Fraction 0.99 -1.11 0.267 0.97  - 1.01 0.98 -1.27 0.205 0.95 – 1.01 
Maximal LV wall thickness 0.99 -0.12 0.902 0.90 - 1.09 1.05 0.61 0.539 0.90 – 1.23 
Indexed LV mass 1.00 -0.15 0.878 0.99 -  1.01 1.00 -0.15 0.883 0.98 – 1.02 
RV end diastolic volume index 0.98 -2.20 0.028 0.96 - 1.00 0.96 -2.21 0.027 0.93 – 1.00 
RV Ejection Fraction 1.00 -0.03 0.973 0.97 - 1.03 1.01 0.35 0.728 0.96 – 1.06 
Indexed LA volume 1.01 1.38 0.167 1.00 - 1.03 1.02 1.92 0.056 1.00 – 1.04 
CMR AoV regurgitant fraction 0.97 -1.84 0.066 0.93 - 1.00 0.96 -1.19 0.233 0.90 – 1.03 
Valvulo-Arterial Impedance 1.04 0.23 0.817 0.77 - 1.40 0.98 -0.08 0.938 0.58 – 1.65 
Late gadolinium enhacement (LGE) 
LGE presence / absence 2.05 2.25 0.025 1.09  -  3.84 2.42 1.68 0.093 0.86 – 6.80 
LGE pattern         
Non-infarct pattern  2.11 2.22 0.027 1.08  -  4.06 2.03 1.24 0.214 0.66 – 6.21 
Infarct pattern  1.90 1.45 0.147 0.80 -  4.54 3.52 1.99 0.047 1.02 – 12.15 
LGE mass, per 1% increase  1.05 1.21 0.226 0.97 -  1.13 1.07 1.24 0.214 0.96 – 1.18 
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3.3 TABLE S3: UNIVARIATE PARAMETERS – Transcatheter Aortic Valve Replacement. 
Parameter TAVR (n=275) TAVR (n=275)  
 All Cause Mortality (n=93) Cardiovascular Mortality (n=51) 
 HR Z P value 95% CI HR Z P value 95% CI 
Baseline Demographics         
Age* 1.43 2.55 0.011 1.09 – 1.89 1.65 2.54 0.011 1.12 – 2.42 
Male Gender 0.94 -0.32 0.751 0.62 – 1.41 0.83 -0.65 0.513 0.48 – 1.44 
BMI 0.97 -1.55 0.122 0.93 – 1.01 0.96 -1.59 0.113 0.91 – 1.01 
Atrial Fibrillation 1.47 1.61 0.107 0.92 – 2.35 1.68 1.67 0.096 0.91 – 3.07 
Diabetes Mellitus 1.07 0.27 0.785 0.67 – 1.70 1.53 1.46 0.144 0.86 – 2.73 
Hypertension 1.20 0.87 0.386 0.80 – 1.81 1.34 1.04 0.301 0.77 – 2.32 
Bicuspid AoV 0.30 -1.70 0.089 0.07 – 1.20 0.24 -1.43 0.154 0.03 – 1.72 
Previous CAD  1.10 0.43 0.671 0.72 – 1.66  1.25 0.77 0.442 0.71 -  2.18 
Previous PCI or CABG  1.01 0.04 0.968 0.65 - 1.58 1.19 0.59 0.558 0.67 – 2.11 
Previous MI 1.10 0.33 0.745 0.61 – 1.99 0.89 -0.31 0.758 0.42 – 1.89 
Baseline Medications         
  ACE inhibitor or ARB 1.06 0.24 0.810 0.67 - 1.66 1.01 0.031 0.975 0.56 - 1.82 
  β-blocker 1.24 1.01 0.311 0.82 -  1.86 1.27 0.85 0.394 0.73 - 2.21 
  Aldosterone Antagonist 0.60 -1.11 0.266 0.24 -  1.48 0.99 -0.03 0.980 0.39  -  2.50 
  Statin 0.90 -0.49 0.621 0.59  - 1.38 0.90 -0.36 0.719 0.51 - 1.60 
STS score 1.10 3.36 <0.001 1.04 – 1.16 1.12 3.37 <0.001 1.05 – 1.20 
Euroscore 1.04 1.67 0.095 0.99 – 1.10 1.07 2.23 0.026 1.01 – 1.13 
Echo Data         
Mean AoV gradient  1.00 0.00 1.000 0.98 – 1.01 0.99 -0.98 0.329 0.96 – 1.01 
Peak AoV gradient  1.00 -0.53 0.595 0.99 – 1.01 0.99 -1.23 0.218 0.97 – 1.01 
AoV area 0.99 -0.01 0.988 0.25 – 3.97 1.34 0.31 0.754 0.21 – 8.60 
AoV area Indexed to BSA 1.94 0.52 0.600 0.16- 23.35 5.93 1.08 0.282 0.23 - 151.6  
Estimated PA pressure         
Moderate  1.74 1.64  0.102 0.90 – 3.38 1.91 1.41 0.160 0.77 – 4.72 
Severe 2.40 1.95 0.052 0.99 – 5.77 2.98 1.94 0.053 0.99 – 9.00 
CMR data         
LV end diastolic volume index 1.00 -0.02 0.983 0.99 – 1.01 1.00 0.05 0.961 0.99 – 1.01 
Indexed LV Stroke Volume 0.97 -3.52 <0.001 0.95 – 0.98 0.96 -2.97 0.003 0.94 – 0.99 
LV Ejection Fraction 0.98 -3.03 0.002 0.97 – 0.99 0.97 -3.32 <0.001 0.95 – 0.99 
Maximal LV wall thickness 0.97 -0.70 0.485 0.91 – 1.05 0.96 -0.76 0.446 0.87 – 1.06 
Indexed LV mass 1.00 0.57 0.567 0.99 – 1.01 1.00 0.75 0.456 0.99 – 1.02 
RV end diastolic volume index 1.00 -0.30 0.764 0.99 _ 1.01 1.00 0.17 0.867 0.99 – 1.02 
RV Ejection Fraction 0.97 -3.29 <0.001 0.96 – 0.99 0.96 -3.52 <0.001 0.94 – 0.98 
Indexed LA volume 1.00 0.95 0.341 1.00 – 1.01 1.01 1.23 0.218 1.00 – 1.02 
CMR AoV regurgitant fraction 1.00 -0.37 0.709 0.98 – 1.02 0.98 -1.09 0.277 0.96 – 1.01 
Valvulo-Arterial Impedance 1.08 0.74 0.457 0.89 – 1.31 1.11 0.77 0.440 0.85 – 1.45 
Late gadolinium enhancement (LGE) 
LGE presence / absence 2.21 3.09 0.002 1.34 – 3.66 3.45 3.17 0.001 1.60 – 7.40 
LGE pattern         
Non-infarct pattern 2.37 3.04 0.002 1.36 – 4.13 3.46 2.96 0.003 1.52 – 7.88 
Infarct pattern 2.05 2.44 0.015 1.15 – 3.66 3.43 2.89 0.004 1.49 – 7.90 
LGE mass, per 1% increase 1.07 3.36 <0.001 1.03 – 1.11 1.07 2.89 0.004 1.02 – 1.12 
*Using age variable scaled by epochs of 10. 
Abbreviations: TAVR, transcatheter aortic valve replacement; BMI, body mass index; BP, blood pressure; CAD, 
coronary artery disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MI, 
myocardial infarction; ARB, angiotensin receptor blocker; AVA, aortic valve area; PASP, pulmonary artery systolic 
pressure, LV, left ventricle; RV, right ventricle; LGE, late gadolinium enhancement.   
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3.4 TABLE S4: MULTI-VARIABLE MODEL – all cause mortality (SAVR Patients). 
MULTIVARIABLE ANALYSIS TABLE FOR SAVR PATIENTS (LGE Present/Absent) 
 
*Using age variable scaled by epochs of 10. 
Abbreviations: EDV, end-diastolic volume; LGE, late gadolinium enhancement; RV, right ventricle; SAVR, surgical 
aortic valve replacement.   
 
 
3.5 TABLE S5: MULTI-VARIABLE MODEL – All Cause Mortality (TAVR Patients). 
MULTIVARIABLE ANALYSIS TABLE FOR TAVR PATIENTS (LGE Present/Absent) 
 
 TAVR n=275  TAVR n=275 
 ALL CAUSE MORTALITY (n = 93)  Cardiovascular MORTALITY (n = 51) 
Parameter HR Z P value 95% CI Parameter HR Z P value 95% CI 
Baseline Age* 1.76 3.61 <0.001 1.29  -  2.38 Baseline Age 2.09 3.55 <0.001 1.39  -   3.15 
CMR LV EF 1.00 -0.20 0.842 0.98  -  1.02 CMR LV EF 0.99 -0.78 0.437 0.97  -   1.02 
CMR RV EF 0.98 -1.63 0.103 0.96  -  1.00 CMR RV EF 0.98 -1.49 0.136 0.95  -   1.01 
LGE Presence 2.38 3.18 0.001 1.40  -   4.06 LGE Presence 3.47 3.09 0.002 1.58  -   7.65 
 
*Using age variable scaled by epochs of 10. 
Abbreviations: LGE, late gadolinium enhancement; LV, left ventricle; RV, right ventricle; TAVR, transcatheter aortic 
valve replacement. 
 
 
 
  
 ALL SAVR n=399  ALL SAVR n=399 
 ALL CAUSE MORTALITY (n = 52)  Cardiovascular MORTALITY (n = 19) 
Parameter HR Z P value 95% CI Parameter HR Z P value 95% CI 
Baseline Age* 1.53 2.48 0.013 1.09  -   2.14 Baseline Age 1.26 0.88 0.377 0.75  -  2.11 
Atrial Fibrillation 2.79 2.36 0.019 1.19  -   6.57 Atrial Fibrillation 5.60 2.91 0.004 1.75  - 17.91 
Indexed RV EDV 0.99 -0.79 0.428 0.97  -   1.01 Indexed RV EDV 0.98 -1.12 0.261 0.94  -   1.02 
LGE Presence 2.14 2.25 0.025 1.10  -   4.15 LGE Presence 1.97 1.24 0.215 0.67  -   5.78 
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3.6 Table S6: MULTI-VARIABLE MODEL – ALL CAUSE MORTALITY: incorporating 
Pulmonary Artery Systolic Pressure (PASP).  
 
 ALL PATIENTS (n=674) 
ALL CAUSE MORTALITY (n= 145) 
Parameter HR Z P value 95% CI 
Age* 2.00 4.60 <0.0001 1.49   -  2.70 
LGE Presence  1.92 2.20 0.028 1.07   -  3.43 
LV ejection fraction 0.99 -0.75 0.451 0.97   -  1.01 
Atrial fibrillation 1.31 0.74 0.457 0.65   -  2.65 
CAD 0.81 -0.71 0.481 0.45  -  1.45 
AVA (by echo) 1.00 0.001 0.999 0.31  -  3.24 
LV maximal wall thickness 0.96 -0.84 0.398 0.88  -  1.05 
RV ejection fraction 1.02 1.15 0.250 0.99   -  1.05 Estimated	PA	pressure  
        Moderate 
        Severe 
 
1.77 
2.73 
 
1.77 
2.42 
 
0.077 
0.016 
 
0.94   -  3.32 
1.21  -  6.17 
 
*Using age variable scaled by epochs of 10. 
Abbreviations: AVA, aortic valve area; CAD, coronary artery disease; LGE, late gadolinium enhancement; LV, left 
ventricle.   
 
 
 
 
 
  
3.7 Table S7: MULTI-VARIABLE MODEL – ALL CAUSE MORTALITY: incorporating 
coronary revascularization (previous CABG/PCI) instead of CAD.  
 
 ALL PATIENTS (n=674) 
ALL CAUSE MORTALITY (n= 145) 
Parameter HR Z P value 95% CI 
Age* 1.91 5,16 <0.0001 1.49   -  2.44 
LGE Presence  2.30 3.16 <0.002 1.37   -  3.86 
LV ejection fraction 0.99 -0.80 0.425 0.98   -  1.01 
Atrial fibrillation 1.29 0.86 0.391 0.72   -  2.29 
Prior PCI/CABG 1.17 0.63 0.529 0.71  -  1.92 
AVA (by echo) 0.89 -0.24 0.814 0.33  -  2.41 
LV maximal wall thickness 0.93 -1.83 0.068 0.86  -  1.01 
RV ejection fraction 1.00 -0.21 0.833 0.98   -  1.02 
 
*Using age variable scaled by epochs of 10. 
Abbreviations: AVA, aortic valve area; CAD, coronary artery disease; LGE, late gadolinium enhancement; LV, left 
ventricle. 
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3.8 TABLE S8: MULTI-VARIABLE MODEL – percentage scar (All Patients). 
 
MULTIVARIABLE ANALYSIS TABLE FOR ALL PATIENTS (LGE %) 
 
 ALL PATIENTS (n=674)  ALL PATIENTS (n=674) 
 ALL CAUSE MORTALITY (n= 145)  Cardiovascular MORTALITY (n=70) 
Parameter HR Z P value 95% CI Parameter HR Z P value 95% CI 
Age* 2.06 5.56 <0.0001 1.60 – 2.66 Age* 2.04 4.56 <0.0001 1.05 -  1.13 
Atrial Fibrillation 1.38 1.10 0.272 0.78 – 2.42 Male Gender 0.53 -2.42 0.016 0.24 - 0.76 
Previous CAD 1.20 0.81 0.419 0.77 - 1.89 Atrial Fibrillation 1.57 1.52 0.129 0.46 - 1.94 
CMR LV EF 0.99 -0.72 0.474 0.98 - 1.01 Previous CAD 1.48 1.47 0.141 0.86 - 2.83 
Echo AVA 1.06 0.11 0.910 0.39 – 2.88 CMR LV EF 0.98 -2.86 0.004 0.96 - 1.00 
CMR RV EF 1.00 -0.43 0.670 0.97 - 1.02 LGE mass, per 1% increase 1.08 3.20 0.001 1.01 - 1.17 
CMR LV maximal wall thickness 0.94 -1.58 0.113 0.87 – 1.01      
LGE mass, per 1% increase 1.11 3.80 <0.001 1.05 - 1.17      
 
*Using age variable scaled by epochs of 10. 
Abbreviations: AVA, aortic valve area; CAD, coronary artery disease; EF, ejection fraction; LGE, late gadolinium 
enhancement; LV, left ventricle; RV, right ventricle.  
 		
3.9 Table S9: MULTI-VARIABLE MODEL – ALL CAUSE MORTALITY: excluding the 12 
patients with 30-day post intervention mortality.  
 
 ALL PATIENTS (n=662) 
ALL CAUSE MORTALITY (n= 133) 
Parameter HR Z P value 95% CI 
Age* 1.95 5.13 <0.0001 1.51   -  2.57 
LGE Presence  2.46 3.22 0.013 1.42  -  4.27 
LV ejection fraction 0.99 -0.88 0.378 0.98   -  1.01 
Atrial fibrillation 1.19 0.56 0.573 0.65   -  2.20 
CAD 1.15 0.59 0.553 0.72  -  1.86 
AVA (by echo) 0.81 -0.39 0.699 0.28  -  2.33 
LV maximal wall thickness 0.94 -1.56 0.119 0.86  -  1.02 
RV ejection fraction 1.00 -0.27 0.788 0.97   -  1.02 
 
*Using age variable scaled by epochs of 10. 
Abbreviations: AVA, aortic valve area; CAD, coronary artery disease; LGE, late gadolinium enhancement; LV, left 
ventricle.   		
3.10 Table S10: MULTI-VARIABLE MODEL – ALL CAUSE MORTALITY: changing index 
date to time of intervention.  
 ALL PATIENTS (n=662) 
ALL CAUSE MORTALITY (n= 133) 
Parameter HR Z P value 95% CI 
Age* 1.93 5.28 <0.0001 1.51   -  2.47 
LGE Presence  2.16 2.95 0.003 1.30  -  3.61 
LV ejection fraction 0.99 -0.92 0.358 0.98   -  1.01 
Atrial fibrillation 1.33 0.97 0.330 0.75   -  2.36 
CAD 1.19 0.74 0.459 0.74  -  1.87 
AVA (by echo) 1.01 0.02 0.988 0.37  -  2.72 
LV maximal wall thickness 0.93 -1.90 0.058 0.86  -  1.01 
RV ejection fraction 1.00 0.01 0.989 0.98   -  1.02 
 
*Using age variable scaled by epochs of 10. 
Abbreviations: AVA, aortic valve area; CAD, coronary artery disease; LGE, late gadolinium enhancement; LV, left 
ventricle.   
 
